4,4-二氟-[1,1-联苯]-3-羧酸 | 164164-26-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4,4-二氟-[1,1-联苯]-3-羧酸
• 英文名称: 4,4'-difluoro-biphenyl-3-carboxylic acid
• 英文别名: 4,4'-Difluoro-[1,1'-biphenyl]-3-carboxylic acid；2-fluoro-5-(4-fluorophenyl)benzoic acid
• CAS: 164164-26-5
• 化学式: C₁₃H₈F₂O₂
• 分子量: 234.202
• InChiKey: QFOLNTPEYOGOJM-UHFFFAOYSA-N

物化性质

• 沸点：
  378.0±32.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  C.I.酸性橙108 、 4,4-二氟-[1,1-联苯]-3-羧酸 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 4,4'-Difluoro-biphenyl-3-carboxylic acid (2-hydroxy-ethyl)-amide
  参考文献：
  名称：

  Synthesis of monomeric and oligomeric naphtho- and biaryl-fused 1,8-diaza-14-crown-4 macrocycles

  摘要：

  Efficient syntheses of naphtho- and biaryl-fused 1,8-diaza-14-crown-4 macrocycles 4a, 4b, 7a, and 7b and related oligomeric systems 11 and 15 are described, An X-ray structure determination for the N,N-dicyanomethyl substituted macrocycle 8 is reported.

  DOI：

  10.1016/0040-4039(94)02345-c
• 作为产物：
  描述：

  二氧化碳 、 4,4'-二氟联苯 在 四甲基乙二胺 、 仲丁基锂 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 以76%的产率得到4,4-二氟-[1,1-联苯]-3-羧酸
  参考文献：
  名称：

  Synthesis of monomeric and oligomeric naphtho- and biaryl-fused 1,8-diaza-14-crown-4 macrocycles

  摘要：

  Efficient syntheses of naphtho- and biaryl-fused 1,8-diaza-14-crown-4 macrocycles 4a, 4b, 7a, and 7b and related oligomeric systems 11 and 15 are described, An X-ray structure determination for the N,N-dicyanomethyl substituted macrocycle 8 is reported.

  DOI：

  10.1016/0040-4039(94)02345-c

文献信息

• The [1,2,4]Triazolo[4,3‐ <i>a</i> ]pyridine as a New Player in the Field of IDO1 Catalytic Holo‐Inhibitors
  作者：Silvia Fallarini、Irene P. Bhela、Silvio Aprile、Enza Torre、Alice Ranza、Elena Orecchini、Eleonora Panfili、Maria T. Pallotta、Alberto Massarotti、Marta Serafini、Tracey Pirali

  DOI：10.1002/cmdc.202100446

  日期：2021.11.19

  A new player has joined the field of IDO1 catalytic holo-inhibitors: From a structure-based virtual screen, a hit compound displaying an atypical [1,2,4]triazolo[4,3-a]pyridine ring as the heme-binding scaffold was identified. The in silico-guided design of analogues led to the identification of an IDO1 inhibitor with sub-micromolar potency, high metabolic stability and selectivity over TDO and CYP

  一位新玩家加入了 IDO1 催化全息抑制剂领域：从基于结构的虚拟屏幕中，显示出非典型 [1,2,4]三唑并[4,3- a ]吡啶环作为血红素结合的命中化合物支架被识别。类似物的计算机引导设计导致鉴定出一种 IDO1 抑制剂，该抑制剂具有亚微摩尔效力、高代谢稳定性以及对 TDO 和 CYP 酶的选择性。
• EP2 receptor agonists
  申请人：Oxford William Alexander

  公开号：US20050256170A1

  公开（公告）日：2005-11-17

  A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisiting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O., and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R 3 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 4 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 6 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where R N′ is selected from H and C 1-4 alkyl; where one of R P3 and R P4 is —C m alkylene-R 2 and the other of R P3 and R P4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when R P3 is —C m alkylene-R 2 , m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R 2 is tetrazol-5-yl, m+n may be 0; or where one of R P3 and R P4 is —O—CH 2 —R 2 , and the other of R P3 and R P4 is H, n is 0; R N is H or optionally substituted C 1-4 alkyl; R 2 is either: —CO 2 H (carboxy); —CONH 2 ; —CH 2 -OH; or tetrazol-5-yl.

  化合物的化学式(I)：或其盐，溶剂合物和化学保护形式，其中：R5是可选择的取代的C5-20芳基或C4-20烷基基团；A选自以下组：其中X和Y选自O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；以及N和O，其中虚线表示适当位置的双键，Q为N或CH；R3选自H、F、Cl和可选择的取代的C1-4烷基、C1-4烷氧基、C5-7芳基和C5-7芳基-C1-4烷基基团；R4选自H、F、Cl和可选择的取代的C1-4烷基、C1-4烷氧基、C5-7芳基和C5-7芳基-C1-4烷基基团；R6选自H、F、Cl和可选择的取代的C1-4烷基、C1-4烷氧基、C5-7芳基和C5-7芳基-C1-4烷基基团；D选自：B选自以下组：其中RN'选自H和C1-4烷基；其中RP3和RP4中的一个是—Cm烷基-R2，另一个是H，m和n可以为0或1，m+n=1或2；当RP3是—Cm烷基-R2时，m也可以为2或3，m+n=1、2、3或4，当R2为四唑-5-基时，m+n可以为0；或其中RP3和RP4中的一个是—O—CH2—R2，另一个是H，n为0；RN为H或可选择的取代的C1-4烷基；R2为以下之一：—CO2H（羧基）；—CONH2；—CH2-OH；或四唑-5-基。
• EP2 RECEPTOR AGONISTS
  申请人：Oxford Alexander William

  公开号：US20080119526A1

  公开（公告）日：2008-05-22

  A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R 3 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 4 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; R 6 is selected from H, F, Cl and optionally substituted C 1-4 alkyl, C 1-4 alkoxy, C 5-7 aryl and C 5-7 aryl-C 1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where R N′ is selected from H and C 1-4 alkyl; where one of R P3 and R P4 is —C m alkylene-R 2 and the other of R P3 and R P4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when R P3 is —C m alkylene-R 2 , m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R 2 is tetrazol-5-yl, m+n may be 0; or where one of R P3 and R P4 is —O—CH 2 —R 2 , and the other of R P3 and R P4 is H, n is 0; R N is H or optionally substituted C 1-4 alkyl; R 2 is either: —CO 2 H (carboxy); —CONH 2 ; —CH 2 —OH; or tetrazol-5-yl.

  化合物的化学式（I）：或其盐，溶剂合物和化学保护形式，其中：R5是可选取代的C5-20芳基或C4-20烷基基团；A选自以下组：其中X和Y选自以下组：O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；以及N和O，其中虚线表示适当位置的双键，Q为N或CH；R3选自H，F，Cl和可选取代的C1-4烷基，C1-4烷氧基，C5-7芳基和C5-7芳基-C1-4烷基基团；R4选自H，F，Cl和可选取代的C1-4烷基，C1-4烷氧基，C5-7芳基和C5-7芳基-C1-4烷基基团；R6选自H，F，Cl和可选取代的C1-4烷基，C1-4烷氧基，C5-7芳基和C5-7芳基-C1-4烷基基团；D选自：B选自以下组：其中RN'选自H和C1-4烷基；其中RP3和RP4之一为—Cm烷基-R2，另一个为H，m和n可以为0或1，m+n=1或2；当RP3为—Cm烷基-R2时，m也可以为2或3，m+n=1，2，3或4，当R2为四唑-5-基时，m+n可以为0；或其中RP3和RP4之一为—O—CH2—R2，另一个为H，n为0；RN为H或可选取代的C1-4烷基；R2为：—CO2H（羧基）；—CONH2；—CH2—OH；或四唑-5-基。
• EP2 Receptor Agonists
  申请人：Oxford Alexander William

  公开号：US20100261760A1

  公开（公告）日：2010-10-14

  The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.

  本公开提供EP2受体激动剂化合物以及使用这些化合物来治疗可以通过EP2受体激动治疗缓解的疾病的方法。
• US7326732B2
  申请人：——

  公开号：US7326732B2

  公开（公告）日：2008-02-05